Publication: Synthesis and characterization of andrographolide derivatives as regulators of βapp processing in human cells
Issued Date
2021-12-01
Resource Type
ISSN
14203049
Other identifier(s)
2-s2.0-85121507271
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules. Vol.26, No.24 (2021)
Suggested Citation
Arpita Dey, Ran Chen, Feng Li, Subhamita Maitra, Jean Francois Hernandez, Guo Chun Zhou, Bruno Vincent Synthesis and characterization of andrographolide derivatives as regulators of βapp processing in human cells. Molecules. Vol.26, No.24 (2021). doi:10.3390/molecules26247660 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/75897
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Synthesis and characterization of andrographolide derivatives as regulators of βapp processing in human cells
Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, one of the main characteristics of which is the abnormal accumulation of amyloid peptide (Aβ) in the brain. Whereas β-secretase supports Aβ formation along the amyloidogenic processing of the β-amyloid precursor protein (βAPP), α-secretase counterbalances this pathway by both preventing Aβ production and triggering the release of the neuroprotective sAPPα metabolite. Therefore, stimulating α-secretase and/or inhibiting β-secretase can be considered a promising anti-AD therapeutic track. In this context, we tested andrographolide, a labdane diterpene derived from the plant Andrographis paniculata, as well as 24 synthesized derivatives, for their ability to induce sAPPα production in cultured SH-SY5Y human neuroblastoma cells. Following several rounds of screening, we identified three hits that were subjected to full characterization. Interestingly, andrographolide (8,17-olefinic) and its close derivative 14α-(5′,7′-dichloro-8′-quinolyloxy)-3,19-acetonylidene (compound 9) behave as moderate α-secretase activators, while 14α-(2′-methyl-5′,7′-dichloro-8′-quinolyloxy)-8,9-olefinic compounds 31 (3,19-acetonylidene) and 37 (3,19-diol), whose two structures are quite similar although distant from that of andrographolide and 9, stand as β-secretase inhibitors. Importantly, these results were confirmed in human HEK293 cells and these compounds do not trigger toxicity in either cell line. Altogether, these findings may represent an encouraging starting point for the future development of andrographolide-based compounds aimed at both activating α-secretase and inhibiting β-secretase that could prove useful in our quest for the therapeutic treatment of AD.